IL2RG and neoplasm: To confirm whether these EGFR-sdCAR molecules would have therapeutic activity in vivo, we performed a murine xenograft experiment wherein immunodeficient NOD-SCID-IL2Rγ-null (NSG) mice were implanted with 6M H292-lung cancer cells, followed by 5M CAR-T cells delivered intravenously 15 days after tumor injection.